Kushenin Combined with Adefovir Dipivoxil Affects the HBV-DNA Load in Serum, Immune Functions and Liver Functions of Patients with Chronic Hepatitis B

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2017 Dec 30

PMID 29285129

Citations 1

Authors

Jing Feng

Jiandong Huang

Zhiqin Li

Affiliations

Soon will be listed here.

Abstract

This study aimed to explore the effect of kushenin combined with adefovir dipivoxil on the load of hepatitis B virus DNA (HBV-DNA) in serum, in immune functions and in liver functions of patients with chronic hepatitis B. A sample of 80 patients with chronic hepatitis B was selected who were admitted to Weifang People's Hospital for treatment between January, 2013 and December, 2015. They were divided into the observation group (n=40) and the control group (n=40). The patients in both groups received adefovir dipivoxil, while those in the observation group additionally received the kushenin. Variations in HBV-DNA load and transforming growth factor-β1 (TGF-β1) in the two groups were detected before intervention, at 1 month, 3 months and 6 months after intervention. In addition, after intervention, we also observed the changes in CD4, CD8 and CD4/CD8, as well as the levels of immune globulin. Furthermore, in these two groups, we detected the changes in endotoxin in serum before and after intervention, the liver function after intervention, and the variations of hyaluronic acid (HA) and type III procollagen (PCIII) before and after intervention which were used to serve as the indicators for hepatic fibrosis. Results showed that at one month, 3 months and 6 months after intervention, HBV-DNA load and the level of TGF-β1 in the observation group were lower than those in the control group (P<0.05). In the observation group, the HBV-DNA load at 6 months after intervention was the lowest, sequentially followed by the levels at 3 months, at 1 month and before intervention (P<0.05). After intervention, the levels of CD4 and CD8 and CD4/CD8 in the observation group were higher than those in the control group (P<0.05). Moreover, the levels of immunoglobulin M (IgM), immunoglobulin G (IgG) and immunoglobulin A (IgA) were elevated in the observation group compared to the levels in the control group (P<0.05). Additionally, the level of endotoxin in serum, the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBil). Besides, after intervention, the levels of HA and PCIII in the observation group were found to be lower than those in the control group before and after intervention (P<0.05). This study concludes that, for patients with chronic hepatitis B, kushenin combined with adefovir dipivoxil can remarkably decrease the HBV-DNA load, improve their immunity, ameliorate the liver function and delay the onset of liver cirrhosis.

Citing Articles

Kushenin combined with entecavir for chronic hepatitis B: A protocol for a systematic review and meta-analysis.

Wang Y, Zhang J, Jin Y, Xiao X, Zhang Q Medicine (Baltimore). 2020; 99(5):e18898.

PMID: 32000393 PMC: 7004585. DOI: 10.1097/MD.0000000000018898.

References

Luo Q, Deng Y, Cheng F, Kang J, Zhong S, Zhang D . Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. Medicine (Baltimore). 2016; 95(50):e5578. PMC: 5268037. DOI: 10.1097/MD.0000000000005578. View

Li Z, Shen C, Wang Y, Wang W, Zhao Q, Liu Z . Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B. Medicine (Baltimore). 2016; 95(44):e5264. PMC: 5591140. DOI: 10.1097/MD.0000000000005264. View

Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H . The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One. 2016; 11(10):e0164210. PMC: 5053414. DOI: 10.1371/journal.pone.0164210. View

Chen C, Liu B, Ma Y, Zhou Y, Pan X, Zhen R . [Lamivudine, interferon-alpha and oxymatrine treatment for the surviving hepatic failure patients with hepatitis B]. Zhonghua Gan Zang Bing Za Zhi. 2009; 17(7):505-8. View

Sun Y, Zhang X, Xie W, Liu G, He X, Huang Y . Identification of UQCRB as an oxymatrine recognizing protein using a T7 phage display screen. J Ethnopharmacol. 2016; 193:133-139. DOI: 10.1016/j.jep.2016.08.007. View

Lin Y, Pan F, Wang Y, Chen Z, Lin C, Yao L . Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases. Oncol Lett. 2017; 13(1):307-314. PMC: 5244885. DOI: 10.3892/ol.2016.5393. View

Gao Y, Meng Q, Zhang Z, Zhao P, Shang Q, Yuan Q . On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. World J Hepatol. 2016; 8(34):1511-1520. PMC: 5143432. DOI: 10.4254/wjh.v8.i34.1511. View

Zhang Y, Zhan L, Li G, Wang F, Wang Y, Li Y . Dimeric Matrine-Type Alkaloids from the Roots of Sophora flavescens and Their Anti-Hepatitis B Virus Activities. J Org Chem. 2016; 81(15):6273-80. DOI: 10.1021/acs.joc.6b00804. View

Hara Y, Tokodai K, Nakanishi C, Miyagi S, Kawagishi N . Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report. Surg Case Rep. 2016; 2(1):118. PMC: 5083705. DOI: 10.1186/s40792-016-0246-2. View

10.

Zhong J, Ke Y, Zhu S, Wang L, Luo C, Gong W . Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection. Onco Targets Ther. 2016; 9:6897-6907. PMC: 5108611. DOI: 10.2147/OTT.S120062. View

11.

Tacke F, Kroy D . Treatment for hepatitis B in patients with drug resistance. Ann Transl Med. 2016; 4(18):334. PMC: 5066043. DOI: 10.21037/atm.2016.09.19. View

12.

Wang L, Han F, Yan X, Fan Y, Wang K . Relationship between hepatitis B virus reverse transcriptase 181 mutation and S gene mutation in hepatitis B virus chronically infected patients. Cell Mol Biol (Noisy-le-grand). 2016; 62(12):18-23. DOI: 10.14715/cmb/ 2016.62.12.4. View

13.

Ma Z, Li Q, Wang J, Zhao Y, Zhong Y, Bai Y . Combining Oxymatrine or Matrine with Lamivudine Increased Its Antireplication Effect against the Hepatitis B Virus In Vitro. Evid Based Complement Alternat Med. 2013; 2013:186573. PMC: 3564270. DOI: 10.1155/2013/186573. View

14.

Chen C, Liu B, Hu Y, Johnson J, Tang Y . Subacute fulminant hepatic failure with intermittent fever. Hepatobiliary Pancreat Dis Int. 2009; 8(6):657-9. View

15.

Banerjee S, Gunda P, Drake R, Hamed K . Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis. Springerplus. 2016; 5(1):1719. PMC: 5052247. DOI: 10.1186/s40064-016-3404-x. View

16.

Chen J, Shen H, Niu M, Guo Y, Liu X, Han Y . Anti-hepatitis B virus effect of matrine-type alkaloid and involvement of p38 mitogen-activated protein kinase and tumor necrosis factor receptor-associated factor 6. Virus Res. 2015; 215:104-13. DOI: 10.1016/j.virusres.2015.12.005. View

17.

Shen X, Fu B, Liu Y, Guo C, Ye Y, Sun R . NKp30 NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B. Sci Rep. 2016; 6:38778. PMC: 5150634. DOI: 10.1038/srep38778. View

18.

Kan Q, Zhang S, Xu Y, Zhang G, Zhu L . Matrine regulates glutamate-related excitotoxic factors in experimental autoimmune encephalomyelitis. Neurosci Lett. 2013; 560:92-7. DOI: 10.1016/j.neulet.2013.12.031. View

19.

Ye G, Zhu H, Li Z, Ma C, Fan M, Sun Z . LC-MS characterization of efficacy substances in serum of experimental animals treated with Sophora flavescens extracts. Biomed Chromatogr. 2007; 21(6):655-60. DOI: 10.1002/bmc.805. View